Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Stock Short Interest Declines 63.0%

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB – Get Free Report) was the target of a significant decline in short interest during the month of October. As of October 30th, there was short interest totaling 5,139 shares, a decline of 63.0% from the October 15th total of 13,889 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 48,290 shares, the short-interest ratio is currently 0.1 days.

Chemomab Therapeutics Trading Up 5.3%

CMMB stock traded up $0.08 during mid-day trading on Monday, hitting $1.61. 17,583 shares of the company were exchanged, compared to its average volume of 93,786. The business has a 50 day simple moving average of $1.65 and a 200-day simple moving average of $1.74. The stock has a market capitalization of $11.67 million, a PE ratio of -0.76 and a beta of 0.80. Chemomab Therapeutics has a 1-year low of $0.92 and a 1-year high of $2.99.

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last posted its earnings results on Thursday, August 20th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.12).

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CMMB. Wall Street Zen raised shares of Chemomab Therapeutics to a “hold” rating in a report on Saturday, October 3rd. Weiss Ratings upgraded Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Chemomab Therapeutics has a consensus rating of “Reduce”.

View Our Latest Stock Analysis on Chemomab Therapeutics

Chemomab Therapeutics Company Profile

(Get Free Report)

Chemomab Therapeutics is an Israel-based clinical-stage biopharmaceutical company developing treatments for inflammatory and fibrotic diseases. Its research focuses on CCL24, a signaling protein the company believes contributes to inflammation and tissue scarring. The company’s lead candidate, CM-101, is a monoclonal antibody designed to block CCL24. Chemomab has studied the candidate in conditions including primary sclerosing cholangitis and systemic sclerosis. Chemomab was previously a privately held company and became publicly traded in 2021 through a merger with Anchiano Therapeutics.

Further Reading

Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.